Moderna, Inc.
Financials
Valuation Metrics
Moderna, Inc.'s Market Cap is $87.62B. At end of 2025 it was $11.56B. Ranked #193 of 3,116 in US market (top 6%), #58 of 1,472 on NASDAQ (top 4%), #15 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 6%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $87.62B | US#193/3,116 Sec#15/265 |
| Revenue | $2.23B | US#1,359/3,116 Sec#38/265 |
| Net Income | $-3.15B | US—/3,116 Sec—/265 |
| Total Assets | $10.96B | US#938/3,116 Sec#30/265 |
| Net Assets | $6.76B | US#565/3,116 Sec#22/265 |
| Employees | 4,700 | US#1,253/3,116 Sec#31/265 |
| Value | ||
| P/B | 12.96x | US#2,691/3,116 Sec#198/265 |
| P/S | 39.33x | US#2,904/3,116 Sec#162/265 |
| FCF Yield | -1.40% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -46.61% | US#2,657/3,116 Sec#151/265 |
| ROA | -28.75% | US#2,864/3,116 Sec#151/265 |
| Op. Margin | -149.01% | US#2,731/3,116 Sec#128/265 |
| Revenue Growth | -27.14% | US#2,661/3,116 Sec#152/265 |
| Financial Health | ||
| Debt Ratio | 62.12% | US#686/3,116 Sec#144/265 |
| Total Debt | $1.29B | US#1,382/3,116 Sec#39/265 |
| FCF | $-1.22B | US#2,968/3,116 Sec#260/265 |
| Cash | $1.72B | US#464/3,116 Sec#22/265 |
| Current Ratio | 2.29x | US#1,067/3,116 Sec#212/265 |
| Dividend | ||
| Div. Growth | -60.61% | US—/3,116 Sec—/265 |
| Performance | ||
| 1Y Return | 713.07% | US#1/3,116 Sec#1/265 |
| 1M Return | 16.22% | US#785/3,116 Sec#59/265 |
| From 52W High | -13.22% | US#1,054/3,116 Sec#62/265 |
| 1Y MDD | -34.16% | US#1,596/3,116 Sec#85/265 |
| Trading | ||
| Volume | 7,728,691 shares | US#166/3,116 Sec#9/265 |
| Trading Value | $1.72B | US#32/3,116 Sec#2/265 |
| Per Share | ||
| EPS | $-7.94 | US—/3,116 Sec—/265 |
| BPS | $17.04 | US#1,406/3,116 Sec#42/265 |
Company Info
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.